Treatment of Chronic Lymphocytic Leukemia With Alemtuzumab: A Review for Nurses
Purpose/Objectives: To review the use of the monoclonal antibody alemtuzumab in patients with advanced refractory B cell chronic lymphocytic leukemia (B-CLL) and nursing management during treatment.
Data Sources: Published articles, abstracts, book chapters, Web sites, and training material.
Data Synthesis: Alemtuzumab can achieve disease remission in patients with chemorefractory B-CLL; however, management of high-risk patients presents certain challenges. Infusion-related events can be minimized by stepwise administration and appropriate prophylaxis. Cytopenia can be minimized by drug postponement and cytokine support or red blood cell or platelet transfusions. Patients also are at risk for infection because of lymphopenia, and anti-infective prophylaxis is mandatory at initiation of therapy until at least two months post-treatment.
Conclusions: With satisfactory supportive measures in place, patients with chemorefractory B-CLL can experience the benefits of alemtuzumab therapy without excessive toxicity.
Implications for Nursing: Nurses should be familiar with treatment and prophylactic protocols, be ready to offer supportive therapy to control side effects, and invest time in patient education.
Jump to a section
References
Anaissie, E.J., Kontoyiannis, D.P., O'Brien, S., Kantarjian, H., Robertson, L., Lerner, S., et al. (1998). Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Annals of Internal Medicine, 129, 559-566.
Binet, J.L., Auquier, A., Dighiero, G., Chastang, C., Piguet, H., Goasguen, J., et al. (1981). A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer, 48, 198-206.
Byrd, J.C., Waselenko, J.K., Maneatis, T.J., Murphy, T., Ward, F.T., Monahan, B.P., et al. (1999). Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: Association with increased infusion-related side effects and rapid blood tumor clearance. Journal of Clinical Oncology, 17, 791-795.
Cheson, B.D. (1995). Infectious and immunosuppressive complications of purine analog therapy. Journal of Clinical Oncology, 13, 2431-2448.
Cheson, B.D., Bennett, J.M., Grever, M., Kay, N., Keating, M.J., O'Brien, S., et al. (1996). National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood, 87, 4990-4997.
Dighiero, G., & Binet, J.L. (2000). When and how to treat chronic lymphocytic leukemia. New England Journal of Medicine, 343, 1799-1801.
Edwards, B.K., Howe, H.L., Ries, L.A., Thun, M.J., Rosenberg, H.M., Yancik, R., et al. (2002). Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer, 94, 2766-2792.
Gilleece, M.H., & Dexter, T.M. (1993). Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood, 82, 807-812.
Hainsworth, J.D. (2000). Monoclonal antibody therapy in lymphoid malignancies. Oncologist, 5, 376-384.
Hoffman, M., Jansen, D., & Rai, K. (1999). Analysis of response to Campath-1H in patients with B-CLL progressing after fludarabine therapy [Abstract P129]. Hematology and Cell Therapy International Workshop on Chronic Lymphocytic Leukemia, 42, 109.
Keating, M., Coutre, S., Rai, K., Osterborg, A., Faderl, S., Kennedy, B., et al. (2003). Management guidelines for clinical use of alemtuzumab in B-cell chronic lymphocytic leukemia. Manuscript submitted for publication.
Keating, M.J., Flinn, I., Jain, V., Binet, J.L., Hillmen, P., Byrd, J., et al. (2002). Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study. Blood, 99, 3554-3561.
Kovacs, J.A., & Masur, H. (2000). Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. New England Journal of Medicine, 342, 1416-1429.
Lundin, J., Osterborg, A., Brittinger, G., Crowther, D., Dombret, H., Engert, A., et al. (1998). CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: A phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 16, 3257-3263.
Morrison, V.A. (1998). The infectious complications of chronic lymphocytic leukemia. Seminars in Oncology, 25, 98-106.
Osterborg, A., Dyer, M.J., Bunjes, D., Pangalis, G.A., Bastion, Y., Catovsky, D., et al. (1997). Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 15, 1567-1574.
Rai, K., Freter, C.B., Mercier, R.J., Cooper, M.R., Mitchell, B.S., Stadtmauer, E.A., et al. (2002). Alemtuzumab in previously treated chronic lymphatic leukemia patients who also had received fludarabine. Journal of Clinical Oncology, 20, 3891-3897.
Rai, K., & Keating, M. (1999). Chronic lymphocytic leukemia. In J.F. Holland & E. Frei (Eds.), Cancer medicine (pp. 2697-2718). Oxford, UK: Blackwell Science.
Rai, K.R., Sawitsky, A., Cronkite, E.P., Chanana, A.D., Levy, R.N., & Pasternack, B.S. (1975). Clinical staging of chronic lymphocytic leukemia. Blood, 46, 219-234.
Rai, K.R., & Stephenson, J. (2001). Monoclonal antibodies in cancer: The development of Campath-1H. In Campath-1H: Emerging frontline therapy in chronic lymphocytic leukemia. New York: Parthenon.
Ries, L.A., Wingo, P.A., Miller, D.S., Howe, H.L., Weir, H.K., Rosenberg, H.M., et al. (2000). The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer, 88, 2398-2424.